Table 1.
Baseline clinical and pharmacological characteristics of the study patients
| Non-Diabetic (n = 2181) | Good-control DM (n = 291) | Poor-control DM (n = 412) | P-value* | P-value† | P-value‡ | |
|---|---|---|---|---|---|---|
| Age (year) |
57.4 ± 10.8 |
59.9 ± 9.9 |
58.0 ± 9.8 |
<0.0001 |
0.27 |
0.009 |
| Male sex |
1653 (75.8) |
165 (56.7) |
203 (49.3) |
<0.0001 |
<0.0001 |
0.07 |
| Hypertension |
1006 (46.1) |
172 (59.1) |
262 (63.6) |
<0.0001 |
<0.0001 |
0.35 |
| Hyperlipidemia |
1318 (61.5) |
224 (77.8) |
328 (79.6) |
<0.0001 |
<0.0001 |
0.58 |
| Current smoking |
1026 (47.0) |
79 (27.1) |
106 (25.7) |
<0.0001 |
<0.0001 |
0.86 |
| Family history of CAD |
502 (23.1) |
63 (22.1) |
89 (21.6) |
0.77 |
0.45 |
0.78 |
| BMI (kg/m2) |
27.3 ± 4.25 |
28.3 ± 4.1 |
28.2 ± 4.5 |
<0.0001 |
< 0.0001 |
0.85 |
| WC (cm) |
99.4 ± 9.7 |
101.9 ± 9.0 |
102.3 ± 10.1 |
<0.0001 |
< 0.0001 |
0.61 |
| EF < 30% |
68 (4.3) |
7 (3.5) |
17 (5.9) |
0.71 |
0.18 |
0.21 |
| Medications | ||||||
| Insulin |
0 (0) |
17 (6.0) |
69 (17.0) |
<0.0001 |
<0.0001 |
<0.0001 |
| OHA |
0 (0) |
84 (28.9) |
171 (41.5) |
<0.0001 |
<0.0001 |
0.001 |
| ACEIs/ARBs |
1295 (59.4) |
180 (61.9) |
288 (69.9) |
0.35 |
<0.0001 |
0.04 |
| Statins |
1849 (84.8) |
255 (87.6) |
362 (87.9) |
0.121 |
0.06 |
0.912 |
| Beta-blockers | 1915 (87.8) | 244 (83.8) | 355 (86.2) | 0.11 | 0.55 | 0.34 |
Data are presented as mean ± SD or n (%).
* Non-diabetic patients versus good-control (diabetic patients with HbA1c ≤ 7%).
† Non-diabetic patients versus poor-control (diabetic patients with HbA1c > 7%).
‡ Good-control versus poor-control diabetic patients.
ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; EF, ejection fraction; OHA, oral hypoglyceamic agent; WC, waist circumference.